These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2461 related items for PubMed ID: 16673249

  • 1. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A, Karn T, Gätje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhäberle E, Holtrich U, Kaufmann M, Ahr A.
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [Abstract] [Full Text] [Related]

  • 2. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
    Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Vincent A, Vrancken Peeters MT, Nederlof PM, Wesseling J, Rodenhuis S.
    Breast Cancer Res Treat; 2012 Feb; 131(3):827-36. PubMed ID: 21472434
    [Abstract] [Full Text] [Related]

  • 3. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [Abstract] [Full Text] [Related]

  • 4. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
    Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN, Pusztai L.
    Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948
    [Abstract] [Full Text] [Related]

  • 5. Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.
    D'Alfonso T, Liu YF, Monni S, Rosen PP, Shin SJ.
    Am J Surg Pathol; 2010 Apr; 34(4):575-81. PubMed ID: 20216378
    [Abstract] [Full Text] [Related]

  • 6. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    BMC Cancer; 2007 Apr 12; 7():63. PubMed ID: 17430582
    [Abstract] [Full Text] [Related]

  • 7. Breast cancer and neoadjuvant therapy: any predictive marker?
    Vyzula R, Dusek L, Zaloudík J, Demlová R, Klimes D, Selvekerová S.
    Neoplasma; 2004 Apr 12; 51(6):471-80. PubMed ID: 15640958
    [Abstract] [Full Text] [Related]

  • 8. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
    Yasojima H, Shimomura A, Naoi Y, Kishi K, Baba Y, Shimazu K, Nakayama T, Kim SJ, Tamaki Y, Noguchi S.
    Eur J Cancer; 2011 Aug 12; 47(12):1779-88. PubMed ID: 21741827
    [Abstract] [Full Text] [Related]

  • 9. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM.
    Clin Cancer Res; 2007 Apr 15; 13(8):2329-34. PubMed ID: 17438091
    [Abstract] [Full Text] [Related]

  • 10. [Effects of neoadjuvant chemotherapy on estrogen and progesterone receptors and HER-2 in breast cancer].
    Zhao J, Wu YL, Wang YD, Zhao GR, Wang J.
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Dec 15; 24(12):1437-9. PubMed ID: 15604081
    [Abstract] [Full Text] [Related]

  • 11. Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy.
    Kasami M, Uematsu T, Honda M, Yabuzaki T, Sanuki J, Uchida Y, Sugimura H.
    Breast; 2008 Oct 15; 17(5):523-7. PubMed ID: 18534850
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
    Dede DS, Gumuskaya B, Guler G, Onat D, Altundag K, Ozisik Y.
    J BUON; 2013 Oct 15; 18(1):57-63. PubMed ID: 23613389
    [Abstract] [Full Text] [Related]

  • 16. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
    Brouckaert O, Pintens S, Van Belle V, Van Huffel S, Camerlynck E, Amant F, Leunen K, Smeets A, Berteloot P, Van Limbergen E, Decock J, Hendrickx W, Weltens C, Van den Bogaert W, Vanden Bempt I, Drijkoningen M, Paridaens R, Wildiers H, Vergote I, Christiaens MR, Neven P.
    Breast Cancer Res Treat; 2009 May 15; 115(2):349-58. PubMed ID: 18629635
    [Abstract] [Full Text] [Related]

  • 17. Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765).
    Noske A, Loibl S, Darb-Esfahani S, Roller M, Kronenwett R, Müller BM, Steffen J, von Toerne C, Wirtz R, Baumann I, Hoffmann G, Heinrich G, Grasshoff ST, Ulmer HU, Denkert C, von Minckwitz G.
    Breast Cancer Res Treat; 2011 Feb 15; 126(1):109-17. PubMed ID: 21190079
    [Abstract] [Full Text] [Related]

  • 18. alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer.
    Ivanov O, Chen F, Wiley EL, Keswani A, Diaz LK, Memmel HC, Rademaker A, Gradishar WJ, Morrow M, Khan SA, Cryns VL.
    Breast Cancer Res Treat; 2008 Oct 15; 111(3):411-7. PubMed ID: 17968656
    [Abstract] [Full Text] [Related]

  • 19. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer.
    Zhang D, Salto-Tellez M, Putti TC, Do E, Koay ES.
    Mod Pathol; 2003 Jan 15; 16(1):79-84. PubMed ID: 12527717
    [Abstract] [Full Text] [Related]

  • 20. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma.
    Zhou B, Yang DQ, Xie F.
    Chin Med J (Engl); 2008 Mar 05; 121(5):387-91. PubMed ID: 18364105
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 124.